+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Telmisartan Market By Indication (Hypertension and Cardiovascular Risk Reduction), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies), By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 72 Pages
  • March 2021
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5314983
The Europe Telmisartan Market is expected to witness market growth of 5.4% CAGR during the forecast period (2020-2026).

Telmisartan refers to a group of antihypertensive drugs known as angiotensin receptor blockers (ARBs). Using this medication, hypertension (high blood pressure) can be managed & treated. It operates by restricting the action of some substances that constrict the blood vessels, allowing the smooth blood flow & the heart to pump more effectively. Telmisartan is also utilized in reducing the possibility of stroke, heart attack, or death in persons 55 years of age or older who are more prone to cardiovascular diseases. Telmisartan comes as a tablet to be consumed by mouth. Telmisartan drug could be utilized alone or combined with other drugs like amlodipine & hydrochlorothiazide. There are three different forms of this tablet.

There is a common & new term attached with lifestyle i.e. sedentary. Due to hectic lifestyles and air-conditioned work environments of corporates, the requirement for people to remain active has decreased considerably. All these factors are likely to increase lifestyle diseases such as diabetes, cardiovascular, and hypertension diseases. While low physical activity will enhance the possibilities of the disease, the increasing population choosing bad habits such as smoking and alcohol with an aim to relax the nerves is expected to increase the cases of cardiovascular diseases. Telmisartan is utilized in the treatment of all these mentioned conditions. With the rising number of patients, consumption of telmisartan is anticipated to witness a hike during the forecast period.

The Germany market dominated the Europe Online Pharmacies Market by Country in 2019, thereby, achieving a market value of $24 million by 2026. The UK market is exhibiting a CAGR of 5% during (2020 - 2026). Additionally, The France market is poised to grow at a CAGR of 7.4% during (2020 - 2026).

Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).

Scope of the Study

Market Segments covered in the Report:

By Indication
  • Hypertension
  • Cardiovascular Risk Reduction

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Companies Profiled
  • Abbott Laboratories
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC (GSK)
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Telmisartan Market, by Indication
1.4.2 Europe Telmisartan Market, by Distribution Channel
1.4.3 Europe Telmisartan Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Telmisartan Market by Indication
3.1 Europe Hypertension Market by Country
3.2 Europe Cardiovascular Risk Reduction Market by Country
Chapter 4. Europe Telmisartan Market by Distribution Channel
4.1 Europe Hospital Pharmacies Market by Country
4.2 Europe Drug Stores and Retail Pharmacies Market by Country
4.3 Europe Online Pharmacies Market by Country
Chapter 5. Europe Telmisartan Market by Country
5.1 Germany Telmisartan Market
5.1.1 Germany Telmisartan Market by Indication
5.1.2 Germany Telmisartan Market by Distribution Channel
5.2 UK Telmisartan Market
5.2.1 UK Telmisartan Market by Indication
5.2.2 UK Telmisartan Market by Distribution Channel
5.3 France Telmisartan Market
5.3.1 France Telmisartan Market by Indication
5.3.2 France Telmisartan Market by Distribution Channel
5.4 Russia Telmisartan Market
5.4.1 Russia Telmisartan Market by Indication
5.4.2 Russia Telmisartan Market by Distribution Channel
5.5 Spain Telmisartan Market
5.5.1 Spain Telmisartan Market by Indication
5.5.2 Spain Telmisartan Market by Distribution Channel
5.6 Italy Telmisartan Market
5.6.1 Italy Telmisartan Market by Indication
5.6.2 Italy Telmisartan Market by Distribution Channel
5.7 Rest of Europe Telmisartan Market
5.7.1 Rest of Europe Telmisartan Market by Indication
5.7.2 Rest of Europe Telmisartan Market by Distribution Channel
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments
6.2.4.1 Approvals
6.2.4.2 Acquisition and Mergers
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments
6.3.5.1 Approvals
6.3.5.2 Partnerships, Collaborations, and Agreements
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments
6.4.5.1 Partnerships, Collaborations, and Agreements
6.4.5.2 Approvals
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments
6.6.5.1 Product Launches and Product Expansions
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments
6.8.5.1 Approvals
6.8.5.2 Product Launches and Product Expansions
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments
6.9.5.1 Approvals
6.9.5.2 Product Launches and Product Expansions
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments
6.10.5.1 Approvals

Companies Mentioned

  • Abbott Laboratories
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC (GSK)
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)

Methodology

Loading
LOADING...